Oxomemazine

This classification denotes an antimuscarinic agent with the molecular formula C18H22N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 305MB38V1C, chemically known as 10h-phenothiazine-10-propanamine, n,n,beta-trimethyl- but generally known as oxomemazine, which bears US NIH Compound Identifier 5574. European Medicines Agency schedules Oxomemazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09549MIG. The term OXOMEMAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules oxomemazine in its Anatomical Therapeutic Chemical (ATC) Classification. OXOMEMAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxomemazine under HS 29343090 and SITC 51578. As of Q4 2014, OXOMEMAZINE remains the US FDA Preferred Term for this commodity. Oxomemazine bears US NLM identifiers UMLS ID C0768401 and NCI Concept Code C73008. SMILES: S1C2C(N(CC(CN(C)C)C)C3C1CCCC3)CCCC2.